<p>Sanofi has completed its acquisition of Vicebio Ltd, bringing an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) into its portfolio. The deal also expands Sanofi’s capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The addition of this candidate strengthens Sanofi’s position in respiratory vaccines and offers a non-mRNA option to its pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-317248), on December 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

SNYNF

<p>Sanofi has completed its acquisition of Vicebio Ltd, enhancing its vaccine portfolio with an early-stage candidate for RSV and HMPV. This acquisition also incorporates Vicebio's 'Molecular Clamp' technology, strengthening Sanofi's position in respiratory vaccines and offering a non-mRNA option. The original content was published by Sanofi SA via EDGAR on December 12, 2025.</p>

Sanofi Completes Acquisition of Vicebio